NICM
HAE icon

Neo Ivy Capital Management’s Haemonetics HAE Stock Holding History

Neo Ivy Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,276
Closed -$71.9K – 416
2026
Q1 		$71.9K Buy
+1,276
New +$83.1K 0.02% 291
2024
Q3 		– Sell
-40,780
Closed -$3.37M – 319
2024
Q2 		$3.37M Buy
+40,780
New +$3.59M 0.66% 66
2021
Q4 		– Sell
-487
Closed -$44K – 507
2021
Q3 		$44K Buy
+487
New +$30.7K 0.05% 333
2020
Q3 		– Sell
-487
Closed -$44K – 521
2020
Q2 		$44K Buy
487
+2
+0.4% +$202 0.05% 333
2020
Q1 		$48K Buy
+485
New +$52.6K 0.08% 313

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neo Ivy Capital Management's HAE Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 1,276 shares — an estimated $71.9K sold.

Neo Ivy Capital Management first reported a position in HAE in Q1 2020 and held it in 5 quarters. The position peaked at $3.37M in Q2 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 1,276 Haemonetics shares in Q2 2026, an estimated $71.9K.
  • Neo Ivy Capital Management first reported a position in Haemonetics in Q1 2020 and held it in 5 quarters.
  • Neo Ivy Capital Management's Haemonetics position peaked at $3.37M in Q2 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.